Prodromal, prophylactic therapies; blarcamesine and Anavex 3-71.
Right now, it appears that about 20% of American Alzheimer's patients have genetics (or other innate factors) that preclude effective therapy with blarcamesine. Current evidence suggests the drug will be effective for only about 4 out of 5 Alzheimer's patients. Any hope for the others?
Two things, presently, lack evidence (in humans). Could blarcamesine provide useful therapy, keeping Alzheimer's from progressing to any stage of debilitation if it were administered prodromally, before any frank, obvious symptoms appear? As noted before, there are several new tests to determine the prodromal presence of, or susceptibility to eventual Alzheimer's disease. With those tests, middle-aged individuals could be tested in their annual health checkups, and if indicated be treated with blarcamesine before symptoms set in. Yet untested is the notion that early, prodromal administration of blarcamesine could actually slow or prevent the onset of Alzheimer's, even in people with genetics otherwise unfavorable to blarcamesine. The concept of prophylaxis.
Secondly, perhaps even more significant — yet to be tested — will be how Anavex 3-71 might work as both a prodromal prophylactic (pre-symptomatic preventative), or, for the 20% with genetics unfavorable to blarcamesine therapy. Might this other Anavex sigma-1 receptor agonist not be restricted to only the 80% with blarcamesine-favorable genetics. Anavex 3-71, at least as to effective doses (in micrograms, not milligrams; doses lower by a factor of a thousand) is very different from blarcamesine. For Alzheimer's of all genetics, perhaps more effective than blarcamesine.
Important matters yet to be checked in clinical trials.
News 
Market Data 
Discover 
